The combination of zanzalintinib and nivolumab achieved an ORR of 63% and DCR of 90% in treatment-naïve advanced ccRCC. How do these results compare with current standard first-line regimens, and what stands out to you in terms of depth and duration of response?

With a median PFS of 18.5 months observed in the zanzalintinib + nivolumab arm, how might this influence discussions around first-line sequencing, especially in intermediate- and poor-risk RCC patients?

While both combinations showed high DCRs, the fixed-dose nivolumab/relatlimab arm had a lower ORR (40%) and slightly shorter PFS. What could explain this discrepancy in response despite targeting overlapping pathways?

The dose-escalation cohorts helped establish 100 mg zanzalintinib as the preferred dose. What factors likely contributed to this selection, and how important is early dose optimization when combining TKIs with I/O agents?

The dose-finding cohorts included patients with colorectal, prostate, lung, and melanoma cancers. What potential do you see for zanzalintinib-based combinations beyond RCC, particularly in tumors historically resistant to immunotherapy?

Grade 3/4 adverse events like hypertension and hepatic enzyme elevations were notable. In your experience, how manageable are these AEs in clinical practice, and what proactive strategies help preserve treatment continuity?

Exelixis designed zanzalintinib to build on the pharmacologic profile of cabozantinib. From what you've seen in STELLAR-002, is there evidence that zanzalintinib may offer improved tolerability or efficacy in certain settings?

Given the promising early activity in both monotherapy and combination settings, what would you prioritize in a future Phase 3 design—biomarker stratification, combination partners, or head-to-head comparisons with other first-line RCC standards?